Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity.

eLife - 19 Nov 2019

Palmer Adam C, Chidley Christopher, Sorger Peter K

Abstract excerpt

Curative cancer therapies are uncommon and nearly always involve multi-drug combinations developed by experimentation in humans; unfortunately, the mechanistic basis for the success of such combinations has rarely been investigated in detail, obscuring lessons learned. Here, we use isobologram analysis to score pharmacological interaction, and clone tracing and CRISPR screening to measure cross-resistance among...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clustered Regularly Interspaced Short Palindromic Repeats
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Drug Synergism

Share to Drug Therapy, Combination

Share to Lymphoma, B-Cell

Share to Lymphoma, Large B-Cell, Diffuse

Share to Transcription Factor CHOP

Source

Open in PubMed Open full text

Identifiers

PMID: 31742555
DOI: 10.7554/eLife.50036
PMCID: PMC6897534

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity.PMID 31742555Read ↗

A Methodological Workflow to Analyze Synthetic Lethality and Drug Synergism in Cancer Cells.Semantic proximity Read ↗

Defining principles of combination drug mechanisms of action.Semantic proximity Read ↗

A statistical framework for defining synergistic anticancer drug interactionsSemantic proximity Read ↗

Heterogeneous therapy-resistant cancer cells have distinct and exploitable drug sensitivity profilesSemantic proximity Read ↗

Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination TreatmentSemantic proximity Read ↗

Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance.Semantic proximity Read ↗

Combining chemogenomic and gene-dose assays to investigate drug synergySemantic proximity Read ↗

Patient-tailored design of AML cell subpopulation-selective drug combinationsSemantic proximity Read ↗

A CRISPR-drug perturbational map for identifying compounds to combine with commonly used chemotherapeuticsSemantic proximity Read ↗

Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted TherapySemantic proximity Read ↗

Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanismsSemantic proximity Read ↗

Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.